(0) - Approximately One in Five Tapinarof Patients Achieved At Least 90% Disease Clearance - - A Significantly Higher Portion of Psoriasis Patients Experienced Clinically Meaningful Improvements in Itch with Tapinarof Compared to Vehicle - - Improvements in DLQI Exceeded MCID at Week 12 with Statistical Significance Compared to Vehicle - - Data Will Be Included in NDA Submission for Tapinarof, Expected Mid-2021 - Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 (tapinarof 1%, n=340; vehicle, n=170) and PSOARING 2 (tapinarof 1%, n=343; vehicle, n=172), at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021) on April 23-25, 2021.